|View printer-friendly version|
|Array BioPharma Announces Clinical Data Presentations At The 2014 ASCO Annual Meeting|
BOULDER, Colo., May 14, 2014 /PRNewswire/ -- Array BioPharma Inc. (NASDAQ: ARRY) today announced presentations on its MEK inhibitors, binimetinib (MEK162) (co-developing with Novartis) and selumetinib (licensed to AstraZeneca) at the 2014 American Society of Clinical Oncology (ASCO) Annual Meeting, which will be held May 30 – June 3, 2014 in Chicago, Illinois. Both MEK inhibitors are advancing in Phase 3 or pivotal trials: binimetinib is being evaluated in NRAS- and BRAF-mutant melanoma and low-grade serous ovarian cancer. In addition, selumetinib is being evaluated in non-small cell lung cancer, uveal melanoma and thyroid cancer.
Ron Squarer, Chief Executive Officer of Array, noted, "We are encouraged to see six ASCO abstracts reporting clinical results for our two partnered MEK programs, while steady progress continues across the pivotal trials for these programs."
The following is a summary of the presentations that will be given at ASCO:
Trials in Progress posters will also showcase the trial designs for the binimetinib trials in low-grade serous ovarian cancer (MILO) and NRAS mutant melanoma (NEMO).
ASCO's embargo for abstracts in this release will lift on Wednesday, May 14 at 6:00 p.m. EDT. All abstracts can be accessed through the ASCO website, http://abstract.asco.org/. After the presentations and posters are public, they will be available as PDFs on Array's website at www.arraybiopharma.com.
About Array BioPharma Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer. Seven Phase 3 or pivotal studies are already in progress, or are planned to begin this year. These programs include the wholly-owned hematology drug, filanesib (ARRY-520) for multiple myeloma and two partnered cancer drugs, selumetinib (AstraZeneca) and binimetinib (MEK162 / Novartis). For more information on Array, please go to www.arraybiopharma.com.
SOURCE Array BioPharma